ArticleOncoimmunology2015

Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.

Karin Schilbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.